Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of metastatic carcinoma of the colon or rectum
• •* Recurrent or progressive after failing prior fluorouracil and irinotecan chemotherapy, sequentially or in combination, unless unable to tolerate irinotecan
• •Measurable disease
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 to 75
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Granulocyte count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hemoglobin at least 10 g/dL
• •Hepatic:
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• •AST and ALT no greater than 5 times ULN
• •PT/aPTT no greater than 1.2 times ULN
• •Renal:
• •Creatinine no greater than 1.5 mg/dL
• •Creatinine clearance at least 50 mL/min
• •No impaired renal function
• •Cardiovascular:
• •No impaired cardiac function
• •Other:
• •No active infection
• •No other malignancy within the past 5 years except basal cell or squamous cell skin cancer
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior chemotherapy
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy
• •Surgery:
• •Not specified
• •Other:
• •No other concurrent anticancer drugs
• •No concurrent chronic non-steroidal anti-inflammatory agents
• •No concurrent chronic therapeutic anticoagulation